Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey

Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey

Medidata a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and Sanofi today announced an expansion of their partnership to bolster clinical research. This new agreement will take advantage of the Medidata Patient, Data, and Study Experiences building on both organizations' shared vision to boost innovation in studies, speed new therapies to market, and promote health outcomes for people globally.

The Medidata Experiences address the fragmented, standalone tools of the life sciences industry by offering AI-embedded, platform-based solutions across clinical workflows, unifying trial processes, diminishing silos, and reducing costs and delays. Combining these Experiences with Sanofi's pharmaceutical knowledge will advance studies, amplifying the development of therapies with greater precision and impact.

"Sanofi and Medidata have worked together for a decade within clinical research, including a collaboration in 2024," said Gaelan Ritter, global head of digital clinical development, Sanofi. "With this broadened relationship, we will continue harnessing the power of AI, optimizing our clinical trials, and ultimately expediting the delivery of groundbreaking medicines."

Sanofi will employ Medidata's expertise and capabilities in decentralized clinical trials as part of this new enterprise agreement. Medidata will also provide strategic consulting and end-to-end operational support, empowering Sanofi to further streamline research processes.

"Clinical development is complex, and biopharma companies demand a strategic partner who can help them enhance data quality, improve study design, and elevate patient care," said Lisa Moneymaker, chief strategy officer, Medidata. "Through our alliance, Sanofi can leverage our unified solutions, specifically mapped out to meet their core needs, to simplify execution and accelerate the entire clinical development process."

To learn more about the Medidata Experiences, please visit here .

About Medidata
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 36,000 trials and 11 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and one of the largest clinical trial data sets in the industry. More than 1 million registered users across approximately 2,300 customers trust Medidata's seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com . Listen to our latest podcast, from Dreamers to Disruptors , and follow us at @Medidata.

About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. With Dassault Systèmes' 3DEXPERIENCE platform, 370,000 customers of all sizes, in all industries, can collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: www.3ds.com .

About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Contact:

Medidata PR

Medidata.PR@3ds.com

Analyst Relations

medidata.AR@3ds.com

Sanofi PR

Sandrine Guendoul | sandrine.guendoul@Sanofi.com
Evan Berland | evan.berland@Sanofi.com
Léo Le Bourhis | leo.lebourhis@Sanofi.com
Victor Rouault | victor.rouault@Sanofi.com
Timothy Gilbert | timothy.gilbert@Sanofi.com
Léa Ubaldi | lea.ubaldi@Sanofi.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

SNY
The Conversation (0)
Dupixent®  Recommended for EU Approval by the CHMP to Treat Patients with COPD

Dupixent® Recommended for EU Approval by the CHMP to Treat Patients with COPD

Recommendation for adults with uncontrolled COPD with raised blood eosinophils based on data from two landmark Phase 3 trials demonstrating Dupixent significantly reduced exacerbations and improved lung function If approved, Dupixent would be the first-ever targeted therapy for COPD in the EU... Keep Reading...
Update on FDA Priority Review of Dupixent®  for the Treatment of COPD Patients with Type 2 Inflammation

Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the U.S. Food and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License Application (sBLA) for Dupixent ® (dupilumab) as an add-on... Keep Reading...
Dupixent®  Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine

Dupixent® Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine

NOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive pulmonary disease (COPD) with evidence of type 2 inflammation Data support the... Keep Reading...
Dupixent®  sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis

Dupixent® sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis

If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell... Keep Reading...

Latest Press Releases

Related News